MarketFriction

Wockhardt Ltd

NSE WOCKPHARMA · BSE 532300 · Pharmaceuticals
₹2,083.90 -1.53%
NSE close2026-10-01
52 week range1,086.70 - 2,422.30
Market cap₹35,654 Cr.
P/E89.4
Nifty 500Nifty Smallcap 50Nifty Smallcap 100Smallcap 250Nifty Pharma Price band 20% Delivery 35.0%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales753701700739809721743738782888965929
Expenses681664759648699593679666604711740737
Operating Profit7237-59911101286472178177225192
OPM %10%5%-8%12%14%18%9%10%23%20%23%21%
Other Income24810309815-7721156731
Interest767773737360484855605052
Depreciation555558545555535653655355
Profit before tax-35-87-180-6-921-22-1099167189116
Tax %109%-1%-2%167%78%5%105%-1%10%9%13%8%
Net Profit-73-86-177-16-1620-45-1088261164107
EPS in Rs-5.34-5.76-11.02-0.91-1.430.86-1.54-5.544.803.6310.226.52
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales4,4534,0153,9373,5662,8442,7083,2302,6512,7983,0123,3733,564
Expenses3,9594,0023,9353,6042,7252,7712,9322,5492,7072,6192,7212,792
Operating Profit494132-38119-6329810291393652772
OPM %11%0.3%0.1%-1.1%4.2%-2.3%9%3.9%3.2%13%19%22%
Other Income66114-238116133975-163-173176226134
Interest129225255265276249299302305254213217
Depreciation142149150164224246247251223217227226
Profit before tax289-247-641-351-247417-411-624-420-16238463
Tax %13%-9%4%-38%-82%-65%-32%-0%12%256%16%
Net Profit252-226-667-217-43688-279-621-472-57199414
EPS in Rs17.45-13.62-42.30-13.52-4.8147.64-16.94-38.80-30.18-2.8913.1125.17
Dividend Payout %0%-56%0%0%0%0%0%0%0%0%0%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth-3%4%8%18%
Compounded Profit Growth1%-19%43%983%
Stock Price CAGR10%39%111%45%
Return on Equity-2%-3%-1%6%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital555555555555557272778181
Reserves3,3623,7203,2812,7972,6192,6163,3213,7773,2823,2824,2724,859
Borrowings2,3092,6774,1603,7483,3753,5822,6742,1982,1842,3562,0212,233
Other Liabilities1,2131,6221,4861,5281,7641,8941,6962,1682,1131,8991,7261,405
Total Liabilities6,9398,0748,9828,1287,8138,1487,7468,2157,6517,6148,1008,578
Fixed Assets2,1232,8092,7732,8883,0583,5023,3433,4623,0422,8812,7362,791
CWIP1,0071,0361,2441,4331,4451,5851,3791,3421,5391,7222,0332,379
Investments3410563214000000422412
Other Assets3,4684,2284,4033,5933,3093,0603,0243,4113,0703,0112,9092,996
Total Assets6,9398,0748,9828,1287,8138,1487,7468,2157,6517,6148,1008,578
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity355-42-26968183649-287413153219-22390
Cash from Investing Activity-222-105-68463593-1471,471-204-118-138-780-231
Cash from Financing Activity-761931,254-769-776-680-1,171-71-315334409-54
Net Cash Flow5746301-66-500-17813138-280415-393105
Free Cash Flow-76-105-678-238127486-4522022369-37776
CFO/OP73%-8%-1,887%4,697%-583%560%270%171%161%274%-13%63%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days60919489130159124104110818064
Inventory Days250249243174183209256222216201234286
Days Payable136144117122187272223265285240191182
Cash Conversion Cycle17519622014112697157604141123168
Working Capital Days145236-56-51-171-133-116-186-163-2335
ROCE %10%7%-1%-1%-1%-1%-3%1%-0%-1%4%8%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters55.14%54.93%51.60%51.99%51.99%49.09%49.09%49.09%49.09%49.09%49.09%49.09%
FIIs3.03%4.18%5.49%5.94%6.70%6.54%6.82%7.29%7.10%7.00%7.09%7.23%
DIIs0.21%0.30%4.82%4.45%5.08%9.82%10.58%11.00%11.00%10.55%10.96%9.24%
Government0.00%0.00%0.01%0.01%0.02%0.02%0.02%0.02%0.02%0.02%0.04%0.02%
Public41.62%40.59%38.06%37.62%36.21%34.54%33.50%32.60%32.79%33.36%32.84%34.44%
No. of Shareholders1,72,9891,61,8131,46,1381,40,3911,38,1421,42,7101,41,7991,46,9181,37,9461,42,2741,39,0161,66,518

Fundamentals

Market Cap₹ 35,654 Cr.
Current Price₹ 2,194
Stock P/E89.4
Book Value₹ 304
ROCE7.55 %
ROE6.11 %
Dividend Yield0.00 %
Face Value₹ 5.00
Compounded Sales Growth (TTM)18%
Compounded Profit Growth (TTM)983%
Consolidated figures.
Valuation
Market capRs 33,860 Cr
Enterprise valueRs 35,843 Cr
P/E (TTM)82.79x
Price to book6.85x
Price to sales9.50x
EV / EBITDA39.56x
EV / EBIT52.71x
EV / sales10.06x
Price to cash flow86.82x
Earnings yield1.21%
P/E, 3-year average89.69x
P/B, 3-year average3.95x
P/E, 5-year average89.69x
P/B, 5-year average2.70x
Profitability
Operating margin (excl. other income)19.33%
Operating margin (incl. other income)20.10%
EBITDA margin25.42%
Pre-tax margin12.99%
Net profit margin11.48%
Net margin, latest quarter11.41%
ROE4.58%
ROCE6.66%
ROA2.55%
ROE, 3-year average-3.48%
ROCE, 3-year average2.85%
ROA, 3-year average-1.37%
ROE, 5-year average-6.54%
ROCE, 5-year average0.23%
ROA, 5-year average-2.84%
ROIC (approx.)8.21%
Tax rate16.39%
Other income / net worth0.53%
Growth
Sales growth (latest year)11.99%
Sales CAGR, 3 years8.36%
Sales CAGR, 5 years4.49%
Profit CAGR, 5 years-20.86%
Sales growth QoQ-3.73%
Profit growth QoQ-36.14%
Sales growth YoY (latest quarter)25.88%
Per share
EPS (TTM)Rs 25.17
EPS (latest year)Rs 13.11
EPS (latest quarter)Rs 6.52
EPS, 3-year averageRs -6.66
EPS, 5-year averageRs -15.14
Book value per shareRs 304.03
Sales per shareRs 219.34
Cash flow per shareRs 24.00
Free cash flow per shareRs 4.68
Efficiency
Asset turnover0.39x
Fixed asset turnover1.21x
Inventory turnover1.63x
Inventory days224 days
Debtor days64 days
Debtors turnover5.74x
Creditor days182 days
Cash conversion cycle168 days
Working capital days35 days
Leverage
Total debtRs 2,233 Cr
Cash and bankRs 250 Cr
Net debtRs 1,983 Cr
Debt to equity0.45x
Net debt / EBITDA2.19x
Interest coverage3.13x
Current ratio (filing 2026-03-31)1.61x
Quick ratio (filing 2026-03-31)1.06x
Trade payables (filing 2026-03-31)Rs 563 Cr
Owners' fund to total sources57.59%
Debt to assets26.03%
Cash flow
Cash from Operating Activity (latest year)Rs 390 Cr
Cash from Investing Activity (latest year)Rs -231 Cr
Cash from Financing Activity (latest year)Rs -54 Cr
Net Cash Flow (latest year)Rs 105 Cr
Free cash flow (latest year)Rs 76 Cr
FCFE (approx.: FCF + change in debt)Rs 288 Cr
Sales to cash flow8.65x
Statement figures
Net sales (TTM)Rs 3,564 Cr
Net sales (latest year)Rs 3,373 Cr
Sales (latest quarter)Rs 929 Cr
Operating profit excl. other income (latest year)Rs 652 Cr
Operating profit (latest quarter)Rs 192 Cr
Other income (TTM)Rs 134 Cr
EBITDA (TTM)Rs 906 Cr
PBDT (TTM)Rs 689 Cr
Profit before tax (TTM)Rs 463 Cr
Tax (latest year)Rs 39 Cr
Net profit (TTM)Rs 409 Cr
Net profit (latest year)Rs 213 Cr
Net profit (latest quarter)Rs 106 Cr
Depreciation (TTM)Rs 226 Cr
Depreciation (latest quarter)Rs 55 Cr
Interest (TTM)Rs 217 Cr
Cost of goods sold (latest year)Rs 1,448 Cr
Total expenditure (latest year)Rs 2,721 Cr
Total income (latest year)Rs 3,399 Cr
Share capitalRs 81 Cr
ReservesRs 4,859 Cr
Shareholders' fundsRs 4,940 Cr
Total assetsRs 8,578 Cr
Net blockRs 2,791 Cr
Capital work in progressRs 2,379 Cr
InvestmentsRs 412 Cr
ReceivablesRs 588 Cr
InventoryRs 887 Cr
Other liabilitiesRs 1,405 Cr
Shares outstanding (crore)16.25
Ownership
Promoter holding49.09% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/B 6.85 is at the 94th percentile (median 2.74).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodWOCKPHARMANifty 50Difference
1 week-8.9%-2.8% -6.1 pts
1 month+12.6%-6.8% +19.4 pts
3 months+7.5%-7.6% +15.1 pts
6 months+77.2%+0.4% +76.8 pts
1 year+41.2%-9.9% +51.1 pts
2 years+106.7%-13.6% +120.3 pts
3 years+785.8%+14.2% +771.6 pts
5 years+361.7%+27.9% +333.8 pts
70 mutual fund schemes hold about ₹1,854 Cr. Over three months 3 bought more and 67 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Tata Small Cap Fund3.02%396 -14%
HSBC Small Cap Fund1.17%223 -25%
Tata Large & Mid Cap Fund2.40%184 -7%
Invesco India Contra Fund0.60%124 -13%
Bandhan Small Cap Fund0.30%104 -26%
HSBC Flexi Cap Fund1.13%68 -27%
Bank of India Small Cap Fund1.99%66 -30%
ICICI Pru ELSS-Tax Saver Fund0.44%63 -20%
HDFC Large & Mid Cap Fund0.20%62 -13%
ITI Small Cap Fund1.60%58 -22%
HDFC Manufacturing Fund0.53%56 -13%
HDFC Pharma and Healthcare Fund1.61%53 -29%
Mirae Asset ELSS Tax Saver Fund0.19%49 -76%
Mirae Asset Small Cap Fund0.67%38 +26%
HSBC Aggressive Hybrid Fund0.64%38 -13%
Tata Multi Asset Allocation Fund0.70%37 -11%
HSBC India Export Opportunities Fund2.24%30 -26%
Nippon India Nifty Smallcap 250 Index Fund0.70%25 -13%
ITI Focused Fund3.69%23 -14%
ITI Multi Cap Fund1.38%21 -18%
ITI Flexi Cap Fund1.30%21 -17%
Axis Nifty Smallcap 50 Index Fund1.89%14 -17%
Bank of India Mfg & Infra Fund(Q1.44%14 +77%
SBI Nifty Smallcap 250 Index Fund0.70%13 -13%
Motilal Oswal Nifty Smallcap 250 Index Fund0.70%9 -13%

Red flags

F-score 7 of 8
lookRegulator order or action Regulator order or action 2026-08-25: In terms of provisions of Regulation 30 (read with Part A of Schedule III) and other applicable provisions of the SEBI (Listing Obligations
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2024-12-27Muayyad KhorakiwalaImmediate relativeother1,800Gift
2022-03-10Themisto Trustee Company Private LPromotersother1,740,000Rs 54.49 CrPledge Creation
2022-02-28Themisto Trustee Company Private LPromotersother5,220,000Rs 177.65 CrPledge Creation
2021-12-23Themisto Trustee Company Private LPromoter Groupother1,900,000Rs 74.85 CrPledge Creation
2021-11-30Themisto Trustee Company Private LPromoter Groupother400,000Rs 17.42 CrPledge Creation
2021-10-21Themisto Trustee Company Private LPromoter Groupother1,350,000Rs 62.41 CrPledge Creation
2021-10-07Themisto Trustee Company Private LPromoter Groupother98,000Rs 4.71 CrRevokation of Pledge
2021-09-02Themisto Trustee Company Private LPromoter Groupother190,000Rs 7.98 CrPledge Creation
2021-09-01Themisto Trustee Company Private LPromoter Groupother1,240,000Rs 49.98 CrPledge Creation
2021-08-27Pasithee Trustee Company Private LPromoter Groupsell500,000Rs 20.30 CrMarket Sale
2021-08-27Ananke Trustee Company Private LimPromoter Groupsell300,000Rs 11.97 CrMarket Sale
2021-08-26Themisto Trustee Company Private LPromoter Groupother400,000Rs 16.62 CrPledge Creation
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

Jun 2026
Sales ₹929 Cr +25.9% vs Jun 2025. Net profit ₹107 Cr +199.1%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2024-06-21Annual General Meeting
2023-08-07Annual General Meeting
2022-03-08Rights 3:10@ Premium Rs 220 Per Share
2021-07-23 Annual General Meeting
2020-07-24 Annual General Meeting
2019-08-02 Annual General Meeting
2018-07-25 Annual General Meeting
2017-07-24 Annual General Meeting
2016-11-17 Interim Dividend Rs 10/- Per Share (Purose Revised)
2016-08-04 Annual General Meeting
2015-09-03 Annual General Meeting
2014-11-13Interim Dividend - Rs 20/- Per Share
2014-09-04Annual General Meeting
2014-02-17Interim Dividend - Rs 5/- Per Share
2013-11-07Interim Dividend Rs.5/- Per Share
2013-08-22Annual General Meeting / Dividend Rs.5 Per Share
2012-09-03Annual General Meeting
2011-08-30Annual General Meeting
2010-09-08Annual General Meeting
2009-06-19Annual General Meeting
2008-04-17Agm/Dividend-Rs2.50 Pr Sh
2007-10-26Int Div-Rs.8.75 Per Sh Purpose Revised
2007-05-10Agm
2007-03-22Interim Dividend-100%
2006-06-21Agm/Div-Rs.5/- Per Sh
DateTypeWhat it says
2026-08-25Regulatory actionIn terms of provisions of Regulation 30 (read with Part A of Schedule III) and other applicable provisions of the SEBI (Listing Obligations and Disclo...
2026-08-10Shareholder meetingDisclosures relating to the 27th Annual General Meeting of Wockhardt Limited held on 10th August, 2026: A) Proceedings of the 27th AGM B) Scrutinizers...
2026-08-10Monitoring Agency ReportPursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 173A of the SEBI (I...
2026-08-10Press ReleaseA press release dated August 10, 2026, titled Wockhardt Antibiotic Academy, an initiative for Patient-Centric Scientific Dialogue to Tackle Multidrug...
2026-08-10Press ReleasePursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on theUnaudited Financial Results (Standalone and Consolidate...
2026-08-10Board meeting outcomePursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regul...
2026-08-05Shareholder meetingNotice of Annual General Meeting to be held on August 10, 2026
2026-07-17Shareholder meetingThe 27th Annual General Meeting ( 27th AGM ) of the Members of Wockhardt Limited will be held on Monday, 10th August, 2026 at 3:30 p.m. (IST), through...
2026-06-30Disclosure under SEBI TakeovWockhardt Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial...
2026-06-11Concall / analyst meetPursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations andDisclosure Requirements) Regulations, 2015, as amended...
2026-06-04Investor PresentationInvestor Presentation
2026-06-01Concall / analyst meetPursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish t...
2026-05-30Press ReleaseA press release dated May 29, 2026, titled " Wockhardt Receives U.S. FDA Approval for ZAYNICH (cefepime and zidebactam), a Novel Intravenous Antibiot...
2026-05-28Press ReleasePursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release titled, Indian drug regulator grants marketing authorization to W...
2026-05-21Credit RatingCredit Rating
2026-05-04Monitoring Agency ReportPursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 173A of the SEBI (I...
2026-05-04Change in ManagementIn terms of provisions of Regulation 30 (read with Part A of Schedule III) and other applicable provisions of the SEBI (Listing Obligations and Disclo...
2026-05-04Press ReleasePursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on theAudited Financial Results (Standalone and Consolidated)...
2026-05-04Board meeting outcomePursuant to Regulation 30 and 33 of Listing Regulations read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disc...
2026-05-04Board meeting outcomePursuant to Regulation 30 and 33 of Listing Regulations read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disc...
2026-03-30Press ReleasePursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release -"Wockhardts Zaynich® (Zidebactam/Cefepime) Receives Favourable R...
2026-02-19General UpdatesPursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular SEBI/HO/CFD/P...
2026-02-10Monitoring Agency ReportPursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 173A of the SEBI (I...
2026-02-10Press ReleasePursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolida...
2026-02-10Board meeting outcomePursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regul...
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Scrip PE is greater than 50 (4 trailing quarters)

Quick answers

What is the market cap of Wockhardt Ltd?

Wockhardt Ltd (WOCKPHARMA) has a market capitalisation of Rs 35,654 Cr. at the 2026-10-01 close.

What is the P/E ratio of Wockhardt Ltd?

Wockhardt Ltd trades at a P/E of 89.4 on trailing twelve-month profit, at the 2026-10-01 close.

What were Wockhardt Ltd's latest quarterly results?

In the Jun 2026 quarter, Wockhardt Ltd sales was Rs 929 Cr (+25.9% vs Jun 2025) and net profit was Rs 107 Cr.

What is the 52-week high and low of Wockhardt Ltd?

The 52-week high is Rs 2,422.30 and the 52-week low is Rs 1,086.70.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03